Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) more than doubled on a year-on-year basis to ₹206.7 crore, a growth of 105.5% from last year’s June quarter.
EBITDA margin expanded by over 9 percentage points to 28.49% from 19.21% during the year-ago quarter.Net profit for the period also more than doubled, increasing by 129% year-on-year to ₹117 crore.
Brokerage firm Avendus had initiated coverage on Navin Fluorine last month with a “buy” recommendation.It stated that the Navin Fluorine is positioned as a partner of choice for global innovators, leading to its asset turn rising from 0.9x to 1.2x by financial year 2027.
The brokerage also expected the CDMO business to see greater stability and reduce earnings volatility with commissioning of larger cGMP facilities, capable of handling late-stage and mature molecules.
Jefferies too maintained its “buy” rating on Navin Fluorine with a price target of ₹5,280. It expected strong growth from financial year 2028, aided by new contracts in the specialty chemicals, CDMPO and high performance products (HPP), which may materialise this financial year.
Shares of Navin Fluorine ended 1% higher on Wednesday ahead of the earnings announcement at ₹5,198. The stock hit a new high of ₹5,245 in today’s trading session and has already rallied 60% so far in 2025.
Also Read: A $3 billion chemical maker may be the first to break a long jinx
First Published: Jul 30, 2025 4:31 PM IS